Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial
LIU Meng-Meng, JI Ling, DONG Meng-Yuan, ZHU Xiao-Fan, WANG Hui-Juan
Department of Neonatology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Abstract：Objective To study the efficacy and safety of early intratracheal administration of budesonide combined with pulmonary surfactant (PS) in preventing bronchopulmonary dysplasia (BPD). Methods A prospective randomized controlled trial was designed. A total of 122 infants with a high risk of BPD who were admitted to the neonatal intensive care unit of the Third Affiliated Hospital of Zhengzhou University from January to July 2021 were enrolled. The infants were randomly divided into a conventional treatment group with 62 infants (treated with PS alone at an initial dose of 200 mg/kg, followed by a dose of 100 mg/kg according to the condition of the infant) and an observation group with 60 infants (treated with PS at the same dose as the conventional treatment group, with the addition of budesonide 0.25 mg/kg for intratracheal instillation at each time of PS application). The two groups were compared in terms of the times of PS use, ventilator parameters at different time points, oxygen inhalation, incidence rate and severity of BPD, incidence rate of complications, and tidal breathing pulmonary function at the corrected gestational age of 40 weeks. Results Compared with the conventional treatment group, the observation group had a significantly lower proportion of infants using PS for two or three times (P<0.05). Compared with the conventional treatment group, the observation group had a significantly lower fraction of inspired oxygen at 24 and 48 hours and 3, 7, and 21 days after administration, significantly shorter durations of invasive ventilation, noninvasive ventilation, ventilator application, and oxygen therapy, a significantly lower incidence rate of BPD, and a significantly lower severity of BPD (P<0.05). There was no significant difference in the incidence rate of glucocorticoid-related complications between the two groups (P>0.05). Conclusions Compared with PS use alone in preterm infants with a high risk of BPD, budesonide combined with PS can reduce repeated use of PS, lower ventilator parameters, shorten the duration of respiratory support, and reduce the incidence rate and severity of BPD, without increasing the incidence rate of glucocorticoid-related complications.
LIU Meng-Meng,JI Ling,DONG Meng-Yuan et al. Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial[J]. CJCP, 2022, 24(1): 78-84.
Gallini F, Coppola M, De Rose DU, et al. Neurodevelopmental outcomes in very preterm infants: the role of severity of bronchopulmonary dysplasia[J]. Early Hum Dev, 2021, 152: 105275. PMID: 33227635. DOI: 10.1016/j.earlhumdev.2020.105275.
Yeh TF, Chen CM, Wu SY, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2016, 193(1): 86-95. PMID: 26351971. DOI: 10.1164/rccm.201505-0861OC.
Flayer CH, Ge MQ, Hwang JW, et al. Ozone inhalation attenuated the effects of budesonide on Aspergillus fumigatus-induced airway inflammation and hyperreactivity in mice[J]. Front Immunol, 2019, 10: 2173. PMID: 31572383. PMCID: PMC6753328. DOI: 10.3389/fimmu.2019.02173.
Yang CF, Lin CH, Chiou SY, et al. Intratracheal budesonide supplementation in addition to surfactant improves pulmonary outcome in surfactant-depleted newborn piglets[J]. Pediatr Pulmonol, 2013, 48(2): 151-159. PMID: 22489085. DOI: 10.1002/ppul.22564.
Gie AG, Regin Y, Salaets T, et al. Intratracheal budesonide/surfactant attenuates hyperoxia-induced lung injury in preterm rabbits[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(6): L949-L956. PMID: 32903026. DOI: 10.1152/ajplung.00162.2020.
Yang CF, Jeng MJ, Soong WJ, et al. Acute pathophysiological effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model[J]. Pediatr Neonatol, 2010, 51(4): 219-226. PMID: 20713286. DOI: 10.1016/S1875-9572(10)60042-3.
Moschino L, Nardo D, Bonadies L, et al. Intra-tracheal surfactant/budesonide versus surfactant alone: comparison of two consecutive cohorts of extremely preterm infants[J]. Pediatr Pulmonol, 2021, 56(7): 2114-2124. PMID: 33942570. PMCID: PMC8251959. DOI: 10.1002/ppul.25415.
Yao YL, Zhang GF, Wang F, et al. Efficacy of budesonide in the prevention and treatment of bronchopulmonary dysplasia in premature infants and its effect on pulmonary function[J]. Am J Transl Res, 2021, 13(5): 4949-4958. PMID: 34150079. PMCID: PMC8205685.
Sucasas Alonso A, Pértega Díaz S, Sáez Soto R, et al. Epidemiology and risk factors for bronchopulmonary dysplasia in prematures infants born at or less than 32 weeks of gestation[J]. An Pediatr (Engl Ed), 2021, S1695-4033(21)00153-3. PMID: 33814331. DOI: 10.1016/j.anpedi.2021.03.002. Epub ahead of print.
Rutkowska M, Ho?ejowski R, Helwich E, et al. Severe bronchopulmonary dysplasia—incidence and predictive factors in a prospective, multicenter study in very preterm infants with respiratory distress syndrome[J]. J Matern Fetal Neonatal Med, 2019, 32(12): 1958-1964. PMID: 29295665. DOI: 10.1080/14767058.2017.1422711.
Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants[J]. J Pediatr, 2010, 156(4): 537-541. PMID: 20138301. DOI: 10.1016/j.jpeds.2009.10.049.
